Biotechnology The US Food and Drug Administration has granted Breakthrough Therapy designation for Braftovi (encorafenib), in combination with Mektovi (binimetinib) and cetuximab, intended to expedite development and review of drugs for serious conditions, where preliminary clinical evidence indicates that they may demonstrate substantial improvement over existing therapies. 7 August 2018